Here we demonstrate that pramipexole, an antiparkinsonian dopamine receptor agonist drug, exerts neuroprotective effects against beta-amyloid neurotoxicity. Using a specific protocol to test individually oligomers, fibrils, or unaggregated amyloid beta-peptide, we found prarnipexole able to protect cells against oligorners and fibrils. Unaggregated amyloid beta-peptide was found unable to cause cell death. Fibris and oligomers were also found to produce elevated amount of free radicals, and this effect was prevented by pramipexole. We propose pramipexole may become in the future a coadjuvant in the treatment of neuropathologies, besides Parkinson's disease, where amyloid betapeptide-mediated oxidative injury exerts a relevant role. (c) 2007 Elsevier B.V. All rights reserved.